Complement is recognized as a key player in a wide range of normal as well as disease-related immune, developmental and homeostatic processes. Knowledge of complement components, structures, interactions, and cross-talk with other biological systems continues to grow and this leads to novel treatments for cancer, infectious, autoimmune-or age-related diseases as well as for preventing transplantation rejection. Antibodies are superbly suited to be developed into therapeutics with appropriate complement stimulatory or inhibitory activity. Here we review the design, development and future of antibody-based drugs that enhance or dampen the complement system. © 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1.
A simplified (A) and more detailed (B) overview of the complement system. Activation can be achieved via the classical pathway, the lectin pathway, or the alternative pathway. Initiation of the classical pathway occurs when C1 (C1q in complex with the serine proteases C1r and C1s) interacts with the Fc region of IgG or IgM antibodies attached to antigenic surfaces. In the lectin pathway, mannose-binding lectin (MBL) and ficolins assemble with MBL-associated serine proteases (MASPs). The alternative pathway is induced by C3 hydrolysis, either spontaneously at low rate or enhanced by interaction of C3 with pathogen's cell surfaces. All three pathways lead to the formation of C3 and C5 convertases, which rapidly amplify the complement response. The outcome of complement activation is three-pronged: (1) opsonization of the target surface by C3b, (2) a boost in inflammation through the generation of anaphylatoxins C3a and C5a and subsequent recruitment of effector cells and (3) formation of the terminal membrane attack complex (MAC), which is responsible for target cell lysis. In addition to the processes described above, several complement regulatory proteins (indicated in orange) are able to inhibit complement by inactivation of C3b and C3 convertases, or by preventing successful formation of the MAC. requires a multivalent, high avidity interaction (Burton et al., 1980; Udaka et al., 1986; Utsumi et al., 1985) .
IgM exists naturally in covalently pentameric and hexameric forms (Cattaneo and Neuberger, 1987) . We propose that pentameric and hexameric IgM should be seen as two distinct subclasses (i.e. IgMp and IgMh). IgMp, representing the vast majority (95%) of IgM, is organized as a pentamer associated with a J-chain, which enables its transepithelial transport via the poly-Ig receptor. IgMp therefore is adapted for providing protection at mucosal surfaces. IgMh is organized in a hexamer, which gives it a superior ability to interact with C1q and activate complement, as shown by its greater complement activating potential (approximately onelog compared to IgMp) (Collins et al., 2002) . For IgMp, the C1q binding sites are sequestered, but become available by a star-tostaple conformational change upon antigen binding (Burton, 1986; Czajkowsky and Shao, 2009; Feinstein, 1986) . IgMh, on the other hand, appears to be a planar molecule, in which potential perturbations required for regulation of C1q binding are less clear (Arnold et al., 2005; Muller et al., 2013) .
For IgG antibodies, high avidity C1q binding requires multimerization (Burton, 1986; Diebolder et al., 2014) . It has been long known that multiple closely spaced Fc regions increase the strength of binding of C1q for IgG dramatically (Borsos and Rapp, 1965; Burton, 1985; Hughes-Jones and Gardner, 1978; Kishore et al., 2004) . Recently, we demonstrated that high avidity binding of C1 to human IgG occurs through antibody hexamers that form after the IgG molecules bind antigen on a cell surface (Diebolder et al., 2014) . IgG hexamers are assembled via specific non-covalent interactions between the Fc segments of neighboring IgG molecules (Fig. 2) . The hexamerized antibody complex is thought to form the optimal docking structure for C1 binding and complement activation.
A number of additional factors influence activation of the classical complement pathway (Fig. 2) . The epitope recognized by the antibody is a critical factor in determining its ability to engage the complement system. Indeed antigen size, density, geometry, fluidity, as well as IgG orientation imposed by epitope positioning, have a strong impact (Bindon et al., 1988; Cragg et al., 2003; de Weers et al., 2011; Hughes-Jones et al., 1985; Parce et al., 1983; Pawluczkowycz et al., 2009; Teeling et al., 2004 Teeling et al., , 2006 Xia et al., 1993b ). These observations can be explained by structural prerequisites affecting Fc movement and Fc:Fc positioning required for efficient hexamer formation (Diebolder et al., 2014) . Furthermore, placement of the hexameric platform relative to the cell surface appears of importance. Thus, even though antibodies of the IgG3 isotype demonstrate stronger C1q binding than IgG1 molecules, the latter may induce cell killing more potently, potentially because it situates the C1q binding site more proximal to the cell surface (Bindon et al., 1988; Bruggemann et al., 1987; Diebolder et al., 2014) . The length and flexibility of the hinge region as well as the heterogeneity of glycans in the CH 2 domain are also factors that influence C1q binding and complement activation (Coloma et al., 1997; Dangl et al., 1988; Raju, 2008; Tan et al., 1990) . Finally, IgGmediated complement activation can be dampened by the presence of specific antibodies of other isotypes, such as human IgG4 or IgA, which are both impaired in their interaction with C1q (Davies et al., 2014; Dechant and Valerius, 2001; Kerr, 1990; Labrijn et al., 2008; van der Neut Kolfschoten et al., 2007; Woof and Kerr, 2006) . Such dampening may result from competition for antigen binding and/or from steric interference of antigen-bound IgG4 or IgA with complement factors. Potentially, the binding of complement-impaired isotypes in the close vicinity of IgG1 molecules interferes with Fc:Fc contact formation thereby inhibiting hexamerization, C1q binding and complement activation.
The complement system off balance
An imbalance in complement, either by insufficient or excessive complement activity, can have important pathological consequences (Botto et al., 2009; Grumach and Kirschfink, 2014; Mayilyan, 2012; Lambris, 2013a, 2013b; Skattum et al., 2011) . Antibody-based treatments can be employed to restore the balance in the complement network in order to achieve therapeutic effects (Fig. 3) . Complement inhibition can be beneficial in pathologies where the system is hyperactivated (e.g. sepsis, transplant rejection, ischemia and reperfusion (I/R) injury) or where it is chronically activated and attacks or damages healthy tissues (e.g. autoimmune disease). It is envisioned that such inhibition can be achieved by targeting key components of the complement cascade mediating the initiation, amplification, and/or termination steps of the system (Table 1A) . Antibody-mediated activation of complement, in contrast, can be a valuable approach in the treatment of infectious diseases and cancer. Here, it is anticipated that antibody-based therapy can mediate complement-dependent lysis via Fab-mediated inhibition of specific negative complement regulatory proteins (CRPs), or via Fc-induced complement activation (Table 1B) to eliminate pathogens and infected or malignant cells, respectively. Below, we will first discuss therapeutic approaches for complement inhibition, followed by strategies to induce and augment antibodymediated complement activation.
Antibody-mediated complement inhibition

Autoimmune and inflammatory diseases
Increased complement activation plays an important role in the pathogenesis of several autoimmune and auto-inflammatory diseases (Ballanti et al., 2013; Chen et al., 2010) . This can result from gain of function mutations in complement activation components or dysregulation of CRPs leading to chronic inflammation and tissue damage (Wagner and Frank, 2010) . For example, atypical hemolytic uremic syndrome (aHUS) can be caused by C3 gain of function mutations or CD46 deficiency (Richards et al., 2003; Stuhlinger et al., 1974) . In paroxysmal nocturnal hemoglobinuria (PNH), two critical CRPs (CD55 and CD59) are absent because of somatic mutation of the PIGA gene, leading to a defect in the synthesis of the phosphatidylinositol tails which are required for their attachment to the membrane. The deficiency, amongst others, leads to sensitization of red blood cells to complement-induced cytotoxicity (Bessler et al., 1994; Takeda et al., 1993) . The therapeutic anti-C5 antibody eculizumab, that inhibits terminal pathway initiation, has significant clinical benefit for both PNH and aHUS and is widely used to treat these disorders (Hillmen et al., 2013; Keating, 2013; Wong et al., 2013) . Eculizumab is also in clinical development for many other complement-related indications (Barilla-Labarca et al., 2013) (Table 1) .
Treatment with eculizumab did not show much efficacy in rheumatoid arthritis (RA), an autoimmune disease characterized by chronic inflammation of synovial joints (Barilla-Labarca et al., 2013) . However, selective delivery of an anti-C5 antibody fused to a synovial homing peptide to locally inhibit complement at inflamed joints showed therapeutic potential in prevention or treatment of arthritis in a preclinical animal model for RA (Durigutto et al., 2013; Macor et al., 2012) . Besides anaphylaxis (via C3a and C5a), which is the prominent pathway responsible for tissue damage in arthritis, also opsonization, MAC formation, and subsequent lysis is suggested to play a role in RA pathogenesis (Banda et al., 2012; Okroj et al., 2007; Romero et al., 2013) . Therefore, these features of complement activation are candidate targets for complement inhibition in RA.
Systemic lupus erythematosus (SLE) is another autoimmune disease associated with numerous immune-based abnormalities including, paradoxically, both complement deficiency and complement activation. Deficiencies within the early classical pathway components (C1q, C4 and C2) predispose for development of SLE, whereas complement also takes part in the auto-antibody inflammatory reaction in the disease leading to tissue and organ damage (Bryan and Wu, 2014; Truedsson et al., 2007) . Reducing complement-related inflammatory responses with antibody therapeutics, potentially via the simultaneous inhibition at multiple levels could, therefore, be incorporated in future treatment regimens for SLE, RA and other autoimmune disorders.
Sepsis
Sepsis is characterized by hyperactivation of the complement cascade in a systemic response to severe infection or inflammation. It may be possible to constrain such an exaggerated response with a therapeutic antibody-based approach. C3a and especially C5a would represent favorable targets in this context, as high levels of these anaphylotoxins are thought to contribute to acute tissue injury (Guo and Ward, 2005; Silasi-Mansat et al., 2010) . The antiC5a antibody IFX-1 for example is currently in clinical development for sepsis, although it could be challenging to effectively target this molecule due to its rapid turnover. In addition, it will be important to use C5a inhibiting antibodies that do not cross-react with whole C5 in order to avoid its depletion resulting in reduced MAC formation and cell lysis, thereby potentially increasing the susceptibility to infection (Ward et al., 2012) . Alternatively, the effects of C5a could be neutralized by blocking its receptor C5aR. A proofof-concept for this was provided with antibodies targeting C5aR or another C5a receptor, C5L2, in treating experimental sepsis in mice (Rittirsch et al., 2008) . Upstream factors of C5 could also represent therapeutic targets in sepsis, with C1, C3 or MASP2 antibodies of particular interest.
Simultaneously targeting of complement and Toll-like receptors, that play a role in innate defense against bacteria, was shown to be effective for Staphylococcus aureus-induced inflammation in a human whole blood model and polymicrobial sepsis in mice (Huber-Lang et al., 2014; Skjeflo et al., 2014) . These observations suggest that dampening the immune response with antibody mixtures or bispecific antibodies in a multi-targeting approach may have therapeutic potential.
Age-related degenerative diseases
Complement has been associated with several age-related degenerative diseases. The most advanced antibody therapeutic in this area is focused on age-related macular degeneration (AMD), the primary cause of blindness in the Western world (Bora et al., 2015) . Vision loss in this condition results from a gradual deterioration of light-sensing cells due to chronic low-grade complement activation resulting in inflammation. Since the initial demonstration of an association between complement Factor H polymorphisms and AMD (Edwards et al., 2005; Hageman et al., 2005; Haines et al., 2005; Klein et al., 2005) , additional associations between AMD and other complement component polymorphisms have become apparent (C2, C3, C7, Factor B, Factor D, Factor I, CFHR1/CFHR3) (Ansari et al., 2013; Bergeron-Sawitzke et al., 2009; Dinu et al., 2007; Fagerness et al., 2009; Francis et al., 2009; Stanton et al., 2011; Yates et al., 2007) . This provides opportunities for therapeutic approaches, such as shown for the anti-Factor D antibody lampalizumab, which appeared to be safe and effective for patients with geographic atrophy, the late stage of the dry form of AMD (Weber et al., 2014) . Since inhibiting C5 has shown to dampen the complement response in other pathologies, C5 is also a target for AMD. However, systemic eculizumab treatment did not decrease the progression of late stage AMD and clinical development of eculizumab appears to be halted in this indication (Weber et al., 2014) . Other complement inhibiting antibodies that are currently in clinical development for AMD are administered as direct intravitreal injections to achieve adequate drug levels in the retina or the retinal pigment epithelium (Yehoshua et al., 2014) . The outcome of these trials will indicate whether local complement inhibition is a feasible therapeutic approach in late stage AMD.
Other correlations between complement and aging have been reported. C3 levels have been associated with the development of chronic and age-related diabetes (Engstrom et al., 2005) . Also, in the normal aging mouse and human brain, C1q levels are increased significantly (Stephan et al., 2013) . Interestingly, it was recently described that C1q may activate Wnt signaling via a direct interaction with Frizzled and subsequent C1s-dependent cleavage of the Wnt coreceptors LRP5/6. Together, these observations appear to link C1q with the age-related decline in tissue regeneration (Naito et al., 2012) . Finally, in Alzheimer's disease, complement activation by C1q in amyloid plaques has been suggested to significantly contribute to the pathology (Bonifati and Kishore, 2007; Yasojima et al., 1999) 
Transplant rejection and ischemia/reperfusion (I/R) injury
Immune responses are generally heavily activated following allo-transplantation. The suppression of adaptive and innate immune responses, including complement inhibition, is therefore a prerequisite for successful graft survival. Hyperacute rejection of transplanted solid organs can occur within minutes, due to complement activation by pre-existing antibodies against donor HLA molecules or blood group antigens expressed on the graft. Although the implementation of blood group and histocompatibility screening almost completely prevents the occurrence of hyperacute rejection, the application of efficacious complementinhibiting antibodies could have value for transplantation with donor tissue across ABO-and HLA-barriers as well as in xenotransplantion. Indeed, clinical studies with C5 antibody eculizumab are ongoing to determine its efficacy and safety in ABO-blood groupincompatible transplantation.
Antibodies and complement activation can contribute to acute (days to weeks after transplantation) and chronic (months to years after transplantation) rejection in patients with pre-existing noncomplement fixing HLA antibodies (Otten et al., 2012) and in patients that generate complement-binding donor-specific HLA antibodies de novo after transplantation Safavi et al., 2014) . C4d deposition in diagnostic biopsies from organ transplants has been adopted as a marker for antibody-mediated rejection and is central in clinical decision making (Racusen et al., 2003) . Both clinical and subclinical antibody-mediated rejection have been recognized as major causes of allograft loss (Amico et al., 2009) , which is usually unresponsive to conventional anti-rejection therapy, such as suppression of the T-cell-dependent antibody response, removal of donor reactive antibodies, blocking residual allo-antibodies, and depletion of naive and memory B-cells. Convincing, but still limited, evidence has shown that eculizumab is efficient in preventing both acute and chronic antibody-mediated rejection and clinical studies further extending these results are ongoing .
Graft-versus-host disease (GvHD) is at the other side of the spectrum of clinical complications of allo-transplantation and is mediated by donor T-cells that attack host cells, leading to epithelial tissue injury in skin, intestine, and liver (Shlomchik, 2007) . Totalbody irradiation, a conditioning regimen to permit hematopoietic cell transplantations, contributes to GvHD by activating host dendritic cells. Mouse models of bone marrow transplantation showed that GvHD involved up-regulation and activation of complement components, including C3a and C5a, by the recipient dendritic cells, and expression of CD55, C3aR, and C5aR on the donor Tcells (Kwan et al., 2012; Ma et al., 2012) . Recent findings indicated that immune cell-derived complement also impacts human T-cell immunity and GvHD, creating the possibility of targeting complement for GvHD treatment (Cravedi et al., 2013; Ma et al., 2014) . Complement is involved in I/R injury, a condition which also applies to transplantation. Low oxygen and insufficient nutrient levels during the restriction in blood supply creates inflammatory conditions, which together with oxidative stress during reperfusion of the (transplant) organ leads to tissue damage. Complement plays an important role in such ischemic tissue infarction by anaphylatoxin-mediated immune responses (Peng et al., 2012) and through MAC-directed lysis of parenchymal cells (Zhou et al., 2000) . It is believed that both the classical and the lectin pathways are part of the injurious processes upon I/R (Castellano et al., 2010; Gorsuch et al., 2012; Sacks and Zhou, 2012) . MASP2-deficient mice were protected from gastrointestinal and myocardium I/R injury compared to wild type mice (Schwaeble et al., 2011) and due to encouraging results, a C5 minibody fused with an RGD-motif (Ergidina ,  Table 1A ), has been approved for treatment of I/R injury.
Antibody-mediated complement stimulation
Infectious diseases
The best-known function of complement is the role in protection against microbial infections. The importance of complement in combatting infectious disease is supported by the observation that many pathogens have evolved mechanisms to evade complementdependent elimination (see Supplemental Table 1 for a comprehensive overview). Various bacterial or viral pathogens inhibit complement by the acquisition or mimicking of membrane-bound CRPs that interfere with the complement cascade. Successful elimination of infectious agents by pathogen-specific antibodies could therefore entail the inhibition of the pathogen's evasive CRPs. As an example, hijacking CD59 from the host's cell membrane appears to be a mechanism of HIV-1 to avoid complement-mediated virolysis (Saifuddin et al., 1997 (Saifuddin et al., , 1995 . Indeed, anti-HIV-1 gp120/gp160 polyclonal antibody treatment combined with anti-CD59 antibody or with the CD59-inhibiting recombinant form of the bacterial toxin intermedilysin domain 4 (rILYd4), sensitized HIV-1 to virolysis (Hu et al., 2010; Lan et al., 2014) . The role of complement in protection against HIV-1 infection, however, has been debated as complement activation did not contribute to antibody-mediated protection against HIV-1 infection in a macaque model (Hessell et al., 2007 The development of antibody therapy for the treatment of infectious disease has met with little success when compared to the development of therapies in inflammatory disease and cancer. Currently only palivizumab is widely used in this aria, which is employed as an RSV prophylaxis. The recent progress in the identification of antibodies that react with highly conserved epitopes on diverse variants of a single virus or common epitopes on related viruses, such as for HIV-1, hepatitis C and influenza (Burton et al., 2012; or paramyxoviruses , bears promise for the development of antibody therapy of infectious diseases. Similar strategies are being pursued for treatment of bacterial infections (Garcia-Rodriguez et al., 2007; Theilacker et al., 2012) . Potentially, such antibodies could be combined with strategies to improve their complement activating capabilities, such as described in the next section. In addition, the combination of broadly cross-strain reactive antibodies with strategies to limit complement evasion mechanisms is potentially of interest. In this respect, there is an unexpected paucity in clinical trials with therapeutic antibodies against microbial complement evasion molecules (e.g. as those listed in Supplemental Table 1 ), which can in part be explained by the fact that multiple complement escape mechanisms may be employed making development of therapies targeting single pathways difficult (Foster, 2005; Rooijakkers and van Strijp, 2007; van Wamel et al., 2006) . Antibody combinations against various evasion molecules to increase efficacy and limit escape and resistance should therefore be pursued.
Cancer
The overexpression of certain molecules or expression of neo-antigens in cancer cells provides potential targets for attack by the immune system. However, in progressive disease the natural immune response apparently lacks specificity or potency to limit disease spreading. For many cancer indications, therapeutic monoclonal antibodies are currently available that redirect the immune system to attack and suppress malignant cells. There is accumulating evidence that complement activation contributes to achieve this (Table 1B) . Nevertheless, controversy on the role of complement activation in cancer therapy remains. We will use CD20 antibodies to exemplify the role of complement activation in cancer treatment and give our view on the place for complement in the cancer immunotherapy field.
Rituximab and ofatumumab are both licensed CD20 antibodies that have been shown to employ complement activation for the elimination of malignant B-cells. Ofatumumab has demonstrated superior complement activation and CDC compared to rituximab in a range of in vitro and in vivo studies (see Lindorfer et al., 2014 for a comprehensive review) Barth et al., 2012; Beum et al., 2008; Beurskens et al., 2012; Bologna et al., 2013; Li et al., 2009; Middleton et al., 2015; Pawluczkowycz et al., 2009; Sebejova et al., 2014; Teeling et al., 2004) . Remarkably, ofatumumab allows for much lower CD20 expression levels and the presence of much higher levels of (negative) complement regulatory proteins in complement-mediated cell killing than rituximab (Barth et al., 2012; Teeling et al., 2004; van Meerten et al., 2010) . Based on these latter findings, antibody constructs targeting both CD20 and CD55 or CD59 were developed, which showed increased killing in pre-clinical studies compared to targeting CD20 alone (Macor et al., 2014 (Macor et al., , 2007 Ziller et al., 2005) .
Rituximab and ofatumumab are both type I CD20 antibodies that strongly cluster CD20 into lipid rafts, a feature that is linked to their ability to potently engage complement (Cragg et al., 2003; Deans et al., 2002; Teeling et al., 2004) . The differences in the strength of complement-mediated cell lysis between the two CD20 antibodies have been studied intensively and can be explained by two key molecular differences. Firstly, clustering facilitates intermolecular antibody Fc:Fc contacts that mediate the assembly of IgG hexamers required for optimal C1 binding and complement activation (Diebolder et al., 2014) . Ofatumumab-opsonized cells bind C1q with much higher avidity than rituximab-opsonized cells (Pawluczkowycz et al., 2009) , which suggests that ofatumumab Fc tails assemble more readily into hexameric platforms (with high C1q avidity) than the Fcs in rituximab. This increased clustering potentially also explains the relatively slow functional off-rate of ofatumumab (i.e. its long retention of CDC capacity after target cell opsonization) (Teeling et al., 2004) . We speculate that the ofatumumab epitope on CD20, as well as the antibody's binding orientation, offer a more favorable structural arrangement for hexamer formation compared to rituximab. Secondly, ofatumumab recognizes an epitope that includes the small loop of CD20 and consequently binds more closely to the cell surface than rituximab (Du et al., 2009; Niederfellner et al., 2011; Teeling et al., 2006) . Activated C4 and C3 only exist for a very short period until they are hydrolyzed, during which time they may diffuse away and form a covalent bond either with a cell surface protein or the antibody itself. The potential for cell surface-opsonization with C4 and C3 and subsequent complement proteins therefore is thought to depend on the distance from the cell membrane at which C1 activation occurs (Sim et al., 1981; Teeling et al., 2004; Xia et al., 1993a Xia et al., , 1993b . We believe that a potent ability of ofatumumab to facilitate hexamerization of its Fc segments at close proximity to the cell membrane leads to an unusually effective complement deposition on the target cell surface. This notion is supported by the observation that a much larger fraction of C4b locates to the surface after ofatumumab-induced complement activation compared to that for rituximab (Beurskens et al., 2012) .
The in vivo contribution of complement activation to the mechanism of action of CD20 antibodies in cancer therapy is still heavily debated. In part, this can be explained by the absence of clear-cut correlations between complement polymorphisms and clinical responses after CD20 antibody treatment. In contrast, such correlations convinced the field of the importance of Fc receptor-mediated effector functions (e.g. ADCC) a long time ago (Cartron et al., 2002; Dall'Ozzo et al., 2004) , even though correlations were observed in some indications and not in others (Boross and Leusen, 2012; Dornan et al., 2010; Farag et al., 2004) . A correlation between a single nucleotide polymorphism (SNP) in the C1qA gene (rs172378, also described as C1qA [276] ) with prolonged response rates to rituximab therapy of follicular lymphoma and diffuse large B-cell lymphoma has been described (Jin et al., 2012; Racila et al., 2008) . However, as the SNP does not lead to a change in the C1q amino acid composition, the mechanism is poorly understood and this observation therefore does not provide an insight into the contribution of complement in CD20 antibody therapy . The importance of complement in tumor cell killing thus needs to be drawn from in vitro, in vivo and ex vivo models. A role for complement in therapy is supported by the observations that complement depletion by CVF markedly reduced cell-killing efficacy of rituximab and that in vivo depletion of NK cells and neutrophils does not affect therapeutic activity of rituximab in xenograft models (Boross et al., 2011; Di Gaetano et al., 2003; Golay et al., 2006) . Here, it is important to note that both rituximab and ofatumumab utilize multiple effector mechanisms, including CDC, ADCC (antibody-dependent cellular cytotoxicity), ADCP (antibody-dependent cellular phagocytosis), and CDCC (complement-dependent cellular cytotoxicity). Interestingly, it has been observed that in absence of ADCC and ADCP, in knock-out mice lacking activating Fc receptors, therapy by CD20 antibodies is inhibited (Clynes et al., 2000) , but that in Fig. 4 . Interplay between complement activation and cell-mediated effector mechanisms. Local complement activation results in complement-dependent-cytotoxicity (CDC) of target cells, plus leads to production of opsonins (C3b, iC3b and C4b) and anaphylatoxin C5a. These mediators enable cross-talk between the complement and cellular immune system, which results in combined and synergistic effects. Opsonization of target cells allows complement-dependent-cellular-cytotoxicity (CDCC) via complement receptors (CR) binding of macrophages and NK cells. C5a acts as a chemoattractant for the recruitment of inflammatory cells and up-regulates expression of the activating Fc␥ receptors while it down-regulates the inhibitory receptor Fc␥RIIb. This results in enhanced antibody-dependent-cellular-cytotoxicity (ADCC) and antibody-dependent-cellular-phagocytosis (ADCP).
absence of complement activation, in C1q knock-out mice, the same is achieved (Di Gaetano et al., 2003) . Similarly, whereas complement activation alone was effective against a low tumor cell burden, larger tumor loads required the presence of active Fc receptors, complement, as well as the complement receptor 3 (Boross et al., 2011) . In our view, this emphasizes that complement and cell-mediated functions should not be seen in isolation; these mechanisms contain important links by which they aid each other (Fig. 4) . Indeed, complement activation has been shown to increase the elimination of mAb-opsonized cells via ADCC and ADCP (Boross et al., 2011; de Haij et al., 2010; Teeling et al., 2004 Teeling et al., , 2006 . C5a, furthermore, acts as a potent chemoattractant for the recruitment of inflammatory effector cells and, in addition, up-regulates expression of the activating Fc␥ receptors, while it down-regulates the inhibitory receptor Fc␥RIIb (Godau et al., 2004; Karsten and Kohl, 2012; Shushakova et al., 2002) . Finally, complement opsonization of target cells increased their killing by macrophages via ADCC. Such complement-enhanced cell-mediated cytotoxicity may be crucial for effective tumor cell depletion at high tumor burden (Boross et al., 2011) . Not only for CD20 mAb treatment, but for antibody therapy of cancer in general, we therefore envisage an intricate interplay between complement and cell-mediated effectors, in which local complement activation not only leads to cell killing, but also attracts and activates effector cells leading to additional and synergistic killing activity (Fig. 4) .
A further complicating factor is that the killing mechanisms employed by therapeutic agents, such as CD20 antibodies, that rely on innate effector mechanisms may be depleted. Indeed, rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia (CLL) patients. Sera of treated patients therefore have a reduced capacity to C3b-opsonize and kill CD20-positive cells, unless supplemented with normal serum or component C2 (Kennedy et al., 2004) . In ofatumumab-treated CLL patients it was observed that, following ofatumumab infusion and initial depletion, CLL cells coated with C3d and CD20 antibody could be observed in the blood, suggesting that the combined effects of complement and Fc-mediated effector mechanisms became insufficient for further B-cell depletion soon after dosing. The observed exhaustion was transient as depletion of CLL cells was again apparent at the next doses (Beurskens et al., 2012) . In vitro studies indicated that exhaustion and suboptimal killing were associated with high antibody concentrations, suggesting that it is important to identify optimal antibody dosing regimens aimed at maximizing killing while minimizing effector reservoir exhaustion Beurskens et al., 2012; Zent et al., 2014) .
In summary, convincing evidence exists for a critical role of complement in the in vivo mechanism of action of complement-active antibodies. Herein, complement activation, in addition to its direct cytotoxic effects, attracts and activates effector cells to induce synergistic tumor cell killing.
Improving antibody therapies -restoring or shifting the balance
Complement represents an important target or effector mechanism for a range of therapeutic approaches, as is argued in this review. In this section, we will discuss antibody format and therapy innovations to further optimize, strengthen and develop this approach.
We envisage three main strategies by which antibody-based therapies that target complement activation could be improved: (i) Combination therapies, (ii) Antibody engineering, and (iii) Therapy design.
Combination therapies
Targeting multiple proteins by the use of antibody cocktails or bispecific antibodies is a promising strategy to dampen or recruit complement and to counter immune evasion molecules on pathogens and on cancer cells. In its crudest form, polyclonals exist as antibody preparations derived from immune sera generated in animals. Despite their drawbacks, such non-human polyclonals are still in use as anti-venoms to treat live-threatening conditions resulting from snake bites. The interaction between various animal toxins and the human complement system and its inhibition may provide leads for potential therapeutic intervention (Tambourgi and van den Berg, 2014) .
The development of combination therapies using recombinant antibody technologies has recently been coming of age. Therapies based on the combination of two existing antibodies have progressed up to approval for human use e.g. trastuzumab and pertuzumab (Baselga et al., 2012; Blumenthal et al., 2013; Swain et al., 2013) and technologies to generate antibody cocktails existing of recombinant oligoclonal or polyclonal antibodies are being developed (Andersen et al., 2007; Logtenberg, 2007; Nielsen et al., 2010; Wang et al., 2013) . Bispecific IgG antibodies that combine two distinct antibody binding sites, offering the ability to address two distinct targets with a single antibody, can now be routinely generated and manufactured using recent innovations Kontermann, 2012; Labrijn et al., 2013) . The approach can not only be used to target epitopes on two distinct proteins, but also to target two epitopes on a single protein. The potential of the latter is supported by studies on multiple cell surface antigens that demonstrated increased or synergistic CDC by certain non-cross blocking antibody combinations (Dechant et al., 2008; Fogler et al., 1988; Klitgaard et al., 2013; Macor et al., 2006; Spiridon et al., 2002) and was demonstrated to increase complement activation of CD20 antibodies (Li et al., 2008) .
Combination therapies, by dual or multispecific targeting approaches, may allow the combined inhibition of complement activation pathways to treat complex pathologies, such as discussed for sepsis or RA. Alternatively, these approaches may be employed to maximize the effects of complement activation, such as aimed for in therapies for infectious disease or cancer. Combination therapies of complement activating antibodies with antibodies that inhibit the activity of host or pathogen CRPs could be particularly rewarding.
Antibody engineering
Molecular engineering of functional sites represents a wellestablished approach to inhibit or enhance complement activation of therapeutic antibodies. Mutations in the C1q binding site or the hinge region can be used to selectively abrogate complement activating capabilities (Duncan and Winter, 1988; Hezareh et al., 2001; Xu et al., 2000) . Antibodies in which both complement-mediated and cellular effector functions were knocked out have a.o. been investigated for the treatment of diabetes (Herold et al., 2005; Xu et al., 2000) .
The structure of the hinge region affects antibody flexibility which is correlated with the antibody's capacity to activate complement (Oi et al., 1984) . Hinge modifications to enhance C1q binding and complement activation therefore have been investigated. The requirements of the hinge region for complement activation was however minimal (Brekke et al., 1995) . Varying the hinge length by itself was not sufficient to regulate complement activity in IgG molecules (Dangl et al., 1988; Tan et al., 1990 ) and amino acid modifications in IgG hinge regions only resulted in minor improvements in C1q binding and CDC (Dall'Acqua et al., 2006) . The opportunities for enhancement of complement activation by hinge modification therefore appear to be modest.
A second approach to enhance complement activation is by increasing the affinity of the C1q binding site on IgG. Mutations in or near the C1q binding site can indeed result in enhanced C1q affinity and increased CDC (Idusogie et al., 2001; Moore et al., 2010) . Also IgG1/IgG3 chimeric antibodies show stronger C1q binding and increased CDC capacity (Kellner et al., 2014; Natsume et al., 2008 Natsume et al., , 2009 . A potential drawback of strengthening the binding of C1q to monomeric IgG is that C1q may bind the therapeutic IgG in solution independent of target binding, leading to non-specific effects and/or C1q may bind to very small immune complexes leading to suboptimal complement stimulation.
Glycoengineering provides a third approach to modify complement activation by IgG antibodies. Fc glycosylation linked to the asparagine residue at amino acid position 297 is critical for the binding of IgG Fc to C1q and the induction of CDC and mutating this site strongly impacts C1q interaction (Nimmerjahn and Ravetch, 2008; Wright and Morrison, 1997) . N-glycans in the Fc region vary in terminal residues, in which terminal galactose, N-acetylglucosamine, and mannose residues may affect C1q binding and CDC activity. The opportunities however are limited, as maximal terminal galactosylation of glycans (G2) was reported to increase CDC of the CD20 antibody rituximab up to a maximum of only 2-fold compared to the non-galactosylated (G0) antibody (Ferrara et al., 2006; Raju, 2008) .
Recently, we described a completely novel approach to modulate complement activation by IgG antibodies. This approach builds on our insight into the molecular mechanism of complement activation by IgG. We found that IgG antibodies form hexameric structures after they bind antigen on the cell surface. These hexamers are characterized by extensive intermolecular Fc:Fc contacts that can be manipulated to decrease or enhance complement activating capabilities (Diebolder et al., 2014) . A number of Fc:Fc interface mutations that enhance hexamer formation, C1q binding, and complement activation were identified. The versatility of the approach is suggested by the observation that a mutation of glutamic acid into arginine at position 345 can enhance complement activation of all four IgG isotypes of an antibody against CD38 (Diebolder et al., 2014) . The approach appears particularly attractive to specifically increase the assembly of the functional IgG antibody unit that activates complement. IgG hexamerization could therefore be conceptually applicable in the engineering of therapeutic antibodies with enhanced activity and creates opportunities for potentiating existing or novel monoclonal antibody drugs for which effector functions are essential mechanisms. Application of this novel technology to drug development is currently being pursued.
Therapy design
A third strategy to maximize the effects of complement engagement by therapeutic antibodies is to further improve the design of therapeutic regimens. It has been argued that exaggerated antibody-mediated complement activation could lead to temporary exhaustion of critical complement components and thereby interfere with the efficacy of the treatment. Preclinical studies indeed suggested that a killing optimum is achieved at intermediate antibody concentrations, whereas high antibody concentrations depleted complement, leading to suboptimal cell lysis (Beurskens et al., 2012) . Therapy design affects in vivo characteristics, such as antibody pharmacokinetics, tissue penetration, opsonization, CDCC, ADCC, ADCP and trogocytosis. Different therapeutic regimens, such as more frequent injections with lower antibody doses, may prevent exhaustion and trogocytosis and thereby allow for recovery of effector activity between administrations Beurskens et al., 2012; Lindorfer et al., 2012; Taylor and Lindorfer, 2014; Zent et al., 2014) . Therapies should therefore be carefully designed to take the interplay between complement activation, cell-mediated effector functions, and various other parameters into account. The inclusion of biomarkers to measure complement titers and complement activation products appears critical in this respect. Therapy design represents a highly interesting yet complex field in which further preclinical experiments, in combination with innovative and state-of-the-art clinical studies, are required to increase insight and establish general rules.
Conclusions
Modulation of complement activation represents a powerful strategy with a strong potential for therapeutic antibody approaches in a wide variety of diseases. Novel antibody formats, including bispecific antibodies, antibody combinations and antibodies engineered for optimized complement activating capabilities, provide extensive opportunities for the development of new and improved treatments. To achieve the full potential of these opportunities, it will be critical for pre-clinical and clinical development to collaborate closely to bring together antibody biology, immunology, pharmacology and drug development knowledge in order to optimally tweak clinical trial designs.
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